Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
Crinetics Pharmaceuticals, Inc.
CRNX
NASDAQ·Healthcare·Biotechnology·Mkt cap $4.1B
$42.23
▲ +9.18%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$25.83 - $57.99
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 31.4% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- First-in-class oral selective somatostatin receptor agonists offering improved patient convenience over injectable alternatives
- Focused expertise in rare endocrine diseases with limited competitive landscape and high unmet medical needs
- Advanced clinical pipeline with lead candidate in Phase III, demonstrating clinical validation and de-risking
- Potential for rapid market penetration in niche markets with premium pricing power for orphan/rare disease indications
Bear Case
2 risks
- Low volatility (beta 0.2).
- Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Growth
Strong growth ahead
Strong revenue growth (641% YoY)
Value
Growth premium of 0.0x vs Biotech & Therapeutics peers. Reasonable for this growth rate.
Momentum
Stable
+3.9% over 3m
Quality
Excellent
Emerging growth company (2873% revenue growth). Early stage with higher risk.
Dividend
None
No dividend
Smart-money signal
Who's buying CRNX right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: May 6, 2026
MAY 7, 2026
Reported EPS of -$1.23 vs -$1.22 consensus (-0.8% surprise). Revenue of $10.7M vs $8.5M expected (+26.1%).
EPS surprise · last 4Q
0 of 1 beats
Q2 26
-0.8%
Next: May 6, 2026
Revenue trend · last 8Q
—
—
—
-44%
+158%
—
—
+2873%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$399.0K
$0
$0
$361.0K
$1.0M
$143.0K
$3.9M
$10.7M
Margins · last 8Q
Gross
—
Profit
-1191.0%
Wall Street consensus
8 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
$86.00
▲ +103.6% vs $42.23
Latest: UBS · Jul 2, 2026
2 analysts covering